Li Yiqun, Yang Mingrui, Nan Yanan, Wang Jiaming, Wang Sanjiao, Cui Dongxiao, Guo Jiajian, He Pengfei, Dai Wenxin, Zhou Shuqi, Zhang Yue, Ma Wenfu
School of Life Science, Beijing University of Chinese Medicine, Beijing 102488, China.
Acta Pharm Sin B. 2023 Apr 18;13(7):3043-53. doi: 10.1016/j.apsb.2023.04.007.
an insufficient coat protein complex I (COPI) retrieval signal, the majority of SARS-CoV-2 spike (S) is resident in host early secretory organelles and a tiny amount is leaked out in cell surface. Only surface-exposed S can be recognized by B cell receptor (BCR) or anti-S therapeutic monoclonal antibodies (mAbs) that is the trigger step for B cell activation after S mRNA vaccination or infected cell clearance by S mAbs. Now, a drug strategy to promote S host surface exposure is absent. Here, we first combined structural and biochemical analysis to characterize S COPI sorting signals. A potent S COPI sorting inhibitor was then invented, evidently capable of promoting S surface exposure and facilitating infected cell clearance by S antibody-dependent cellular cytotoxicity (ADCC). Importantly, with the inhibitor as a probe, we revealed Omicron BA.1 S is less cell surface exposed than prototypes because of a constellation of S folding mutations, possibly corresponding to its ER chaperone association. Our findings not only suggest COPI is a druggable target against COVID-19, but also highlight SARS-CoV-2 evolution mechanism driven by S folding and trafficking mutations.
由于衣被蛋白复合体I(COPI)回收信号不足,大多数严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白(S)驻留在宿主早期分泌细胞器中,只有少量泄漏到细胞表面。只有表面暴露的S才能被B细胞受体(BCR)或抗S治疗性单克隆抗体(mAb)识别,这是S mRNA疫苗接种后B细胞激活或S mAb清除感染细胞的触发步骤。目前,尚无促进S在宿主表面暴露的药物策略。在此,我们首先结合结构和生化分析来表征S的COPI分选信号。然后发明了一种有效的S COPI分选抑制剂,显然能够促进S的表面暴露,并通过S抗体依赖性细胞毒性(ADCC)促进感染细胞的清除。重要的是,以该抑制剂为探针,我们发现奥密克戎BA.1 S由于一系列S折叠突变而比原型毒株更少暴露于细胞表面,这可能与其内质网伴侣蛋白结合有关。我们的研究结果不仅表明COPI是抗2019冠状病毒病的可药物化靶点,还突出了由S折叠和转运突变驱动的SARS-CoV-2进化机制。